undamentalytics Newsletter
Sign in

Monopar Therapeutics (MNPR) stock

Add to watchlist

Add holding +

NASDAQ: MNPR Nasdaq Biotechnology Next results ~November 12, 2026

Monopar Therapeutics is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 6 selling1 purchase and 28 sales by directors and officers, last 12 monthsInsider trades
  • Funds60 adding, 38 cuttingOf 24 active managers that changed their stake, 11 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Monopar Therapeutics's latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 12 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 63% and a beta of 1.2 against the S&P 500.
  • Heavily shorted. 24.6% of the shares available to trade are sold short (6.7 days of average volume to cover).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results

Earnings per share
-$0.62 against an average estimate of -$0.65: beat by 4.5%
Share reaction
-3.5% in the first session after the results on August 12, 2026, against +0.9% for the S&P 500
Next report
November 12, 2026; average EPS estimate -$0.85

Monopar Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-5.7%
  • 1 week-6.0%
  • 1 month-15.0%
  • This year+1.5%
  • 1 year-23.1%
  • 5 years+153.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 12, 2026
Next results (est.)
November 12, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Insider trade
  2. Results
  3. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Monopar Therapeutics valuation models and calculator

No model value for Monopar Therapeutics at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, after the close. Analysts expect revenue of $0 and EPS of −$0.85 (range −$1.37 to −$0.37) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$3.04 −64% — 0%
Next −$1.92 +37% $28m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +4.7% on 90 days ago. In the last 30 days, 4 analysts raised Monopar Therapeutics's forecast and 4 cut it.

Consensus EPS forecast Monopar Therapeutics, last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.90 Current fiscal year, 60 days ago: −$2.90 Current fiscal year, 30 days ago: −$3.01 Current fiscal year, 7 days ago: −$3.01 Current fiscal year, Now: −$3.04 −$3.04 Next fiscal year, 90 days ago: −$3.14 Next fiscal year, 60 days ago: −$3.13 Next fiscal year, 30 days ago: −$1.98 Next fiscal year, 7 days ago: −$1.92 Next fiscal year, Now: −$1.92 −$1.92

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.90−$3.14
60 days ago −$2.90−$3.13
30 days ago −$3.01−$1.98
7 days ago −$3.01−$1.92
Now −$3.04−$1.92

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.65 −$0.62 +4.5%
Mar 2026 −$0.90 −$0.46 +48.8%
Dec 2025 −$0.51 −$0.61 −19.1%
Sept 2025 −$0.40 −$0.48 −20.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

12 analysts, Oct 2026
Buy1192%
Hold18%
Sell00%

Monthly trend

  1. Oct 202647112
  2. Sep 202648113
  3. Aug 20264913

Counts of recommendations published by analysts covering Monopar Therapeutics, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
24.6%
of tradable shares
Days to cover
6.72
at average volume
Short interest, 1 month
+34%
to October 15, 2026
Held by institutions
95%
of shares
Held by insiders
23.5%
of shares
Employees
22
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
MNPR−48%−26%−86%+1194%+197%+2%
Industry peers (median)−35%−57%−17%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
MNPR17%33%17%42%67%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
MNPR−70%−60%−92%−67%−46%−47%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since December 19, 2019: 99% from December 20, 2019 to November 20, 2023. Getting back needed a 9243% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$50.12 – $123.84
From 52-week high
−46.5%
vs 50-day average
−26.6%
vs 200-day average
−14.2%
Volatility (1 year)
63%
Beta vs S&P 500
1.25

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±8.1%
After a week
6 up, 6 down
typical move ±11.8%
After a month
4 up, 8 down
typical move ±13.0%
Results releasedNext dayS&P 500 next day5 days21 days
August 12, 2026 −3.5% +0.9% +8.2% −3.7%
May 14, 2026 −3.5% −0.4% +2.0% 0.0%
March 27, 2026 −2.3% −2.0% −1.6% −0.1%
November 13, 2025 −5.5% −1.7% +0.5% −9.0%
August 12, 2025 +6.9% +1.4% +6.9% +52.1%
May 13, 2025 +5.7% +0.8% +5.1% −3.6%
March 31, 2025 −17.1% +1.0% −28.4% +3.7%
November 8, 2024 +5.9% +0.5% +15.0% +45.3%
August 9, 2024 −14.4% +0.5% −15.3% −10.9%
May 9, 2024 −10.4% +0.7% −17.6% +3.3%
March 28, 2024 −7.9% −0.2% −18.3% −11.8%
November 9, 2023 −14.0% +0.8% −22.1% −12.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$576M
Institutions reporting
96
Shares held vs prior quarter
▼ 0.2%
Positions opened / closed
28 / 14

Top buyers and sellers, Q2 2026: 60 institutions bought and 38 sold ; the biggest buyer was Orbimed Advisors LLC (+157K shares) and the biggest seller Sio Capital Management, LLC (−174K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Jupiter Topco LLC $122M 1.3M 21.1% —
RA Capital Management, L.P. $61.8M 667K 10.7% 0.0%
Blackrock, Inc. $32.3M 349K 5.6% ▲ 10.2%
Deerfield Management Company, L.P. $30M 324K 5.2% 0.0%
Saturn V Capital Management LP $28.9M 312K 5.0% ▼ 9.7%
Siren, L.L.C. $25M 270K 4.3% 0.0%
ADAR1 Capital Management, LLC $20.1M 218K 3.5% ▼ 17.7%
Polar Capital Holdings PLC $19.9M 214K 3.4% ▼ 5.3%
Vanguard Capital Management LLC $19.4M 210K 3.4% ▼ 4.0%
Adage Capital Partners Gp, L.L.C. $19.4M 209K 3.4% ▼ 32.3%
Tcg Crossover Management, LLC $18.8M 203K 3.3% ▲ 53.9%
Wellington Management Group LLP $14.7M 158K 2.5% ▼ 9.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Monopar Therapeutics's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $104,925 1 trade by 1 insider, last 12 months Insider sales History → $5.2M 28 trades by 6 insiders · 93% under pre-set plans
Net ▼ $5.1M net selling
Insider Date Trade Shares Price Value
Starr Christopher M Director October 1, 2026 Sell pre-set plan 799 $79.67 $63,656
Starr Christopher M Director October 1, 2026 Sell pre-set plan 2,970 $78.82 $234,095
Starr Christopher M Director October 1, 2026 Sell pre-set plan 4,631 $78.09 $361,635
Robinson Chandler Chief Executive Officer September 24, 2026 Sell pre-set plan 10,450 $87.15 $910,718
Robinson Chandler Chief Executive Officer September 24, 2026 Sell pre-set plan 9,638 $87.96 $847,758
Robinson Chandler Chief Executive Officer September 24, 2026 Sell pre-set plan 8,368 $88.97 $744,501
Robinson Chandler Chief Executive Officer September 24, 2026 Sell pre-set plan 600 $89.79 $53,874
Tsuchimoto Kim R Director August 26, 2026 Sell pre-set plan 485 $108.83 $52,783
Tsuchimoto Kim R Director August 26, 2026 Sell pre-set plan 590 $113.84 $67,166
Tsuchimoto Kim R Director August 26, 2026 Sell pre-set plan 615 $109.56 $67,379
Tsuchimoto Kim R Director August 26, 2026 Sell pre-set plan 700 $110.65 $77,455
Tsuchimoto Kim R Director August 26, 2026 Sell pre-set plan 1,098 $111.84 $122,800

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 12, 2026 estimated from the company's past filing pattern, not announced

  • August 12, 2026
  • May 14, 2026
  • March 27, 2026
  • November 13, 2025
  • August 12, 2025
  • May 13, 2025

Recent SEC filings

Data status

When each part of this page on Monopar Therapeutics was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Monopar Therapeutics in brief

What does Monopar Therapeutics do?
Monopar Therapeutics is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Monopar Therapeutics's stock ticker?
Monopar Therapeutics trades under the ticker MNPR on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Monopar Therapeutics's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Jupiter Topco LLC, RA Capital Management, L.P. and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Monopar Therapeutics stock?
Over the last 12 months, Monopar Therapeutics's directors and officers reported 1 open-market purchases and 28 sales on Form 4. The insider trading page charts every trade.
When is Monopar Therapeutics's next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Monopar Therapeutics announces its own schedule.